US EditionPublished • loading... • Updated
Denali Therapeutics (DNLI) – Analysts’ Recent Ratings Changes
Summary by themarketsdaily.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Denali Therapeutics (DNLI) – Analysts’ Recent Ratings Changes
Several analysts have recently updated their ratings and price targets for Denali Therapeutics (NASDAQ: DNLI): 3/26/2026 – Denali Therapeutics had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an “overweight” rating on the stock. 3/26/2026 – Denali Therapeutics had its price target raised by The Goldman Sachs Group, Inc. […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
